These authors contributed equally to this work.
Introduction
Gastric cancer (GC) is one of the most common causes of death from cancer worldwide (1) . Although accumulating evidence shows that various genetic alterations cause tumorigenesis and tumor progression in GC (2) , in clinical settings, no molecule has been used as an early diagnostic biomarker, and only a few therapeutic targets have been identified (3) , such as the gene amplifications of MET and ERBB2; hypermethylation of p16 (4, 5) ; mutations of TP53, APC and E-cadherin (6) (7) (8) ; oncogenic activation of â-catenin and K-ras (9) ; and inactivation of the mismatch repair gene hMLH1, which is associated with microsatellite instability (10) . Although recent improvements in diagnostic and treatment techniques have contributed to early detection and treatment outcomes, patients with advanced disease still frequently develop recurrent disease despite extended radical resections and consequently present extremely poor survival rates (11) . Therefore, identifying clinical biomarkers and therapeutic molecular targets for GC is urgently needed to improve the survival rate of GC patients.
Zuotin-related factor 1 (ZRF1) has been recently characterized as an epigenetic factor binding H2A-ubiquitin binding protein. Ubiquitination of histone H2A is one of the most representative epigenetic markers and is associated with the functions of the Polycomb complexes, which are associated with gene silencing and have essential functions for cellular differentiation and development (12) (13) (14) (15) . The correlation between Polycomb complexes and cellular differentiation indicates that ZRF1 might have an important role in tumorigenesis (16) . The high overexpression of ZRF1 has been reported in several malignancies, such as acute myeloid leukemia (17) (18) (19) , chronic myeloid leukemia (20) , chronic lymphocytic leukemia (21) and head and neck squamous cell carcinoma (22) . In addition, ZRF1 is located at the critical region of 7q22-31.1, in which genomic high-copy amplification has been reported to contribute to the progression of several kinds of cancer, such as prostate (23) , germ cell (24) , glioblastoma (25, 26) , head and neck squamous cell carcinoma (27) and GC (28) (29) (30) . However, to date, there has been no report on ZRF1 molecular function, its contribution to gastric carcinogenesis, and its clinical and prognostic significance in patients with GC.
In particular, we focused on the relation of ZRF1 function to cell apoptosis and the cell cycle in cancers. A recent study demonstrated that silencing of ZRF1 expression in breast cancer cells by knockdown resulted in induction of apoptosis and DNA damage, upregulation of cleaved PARP and downregulation of BCL2 and H2AUbK119 (31) . In addition, ZRF1 was previously suggested to have a cell cycle-specific function (16, 32) and a function related to cell cycle progression (33, 34) . Furthermore, ZRF1 was reported to be a novel mediator in the activation of ARF, which primarily regulates the activation of the tumor suppressor p53. p53 regulates the cell cycle and triggers apoptosis after DNA damage and plays a key role in a wide range of human cancers, including GC (35) (36) (37) . These findings prompted us to hypothesize that ZRF1 function has a close relation to p53. However, the relationship between p53 and ZRF1 has still not been elucidated.
In this study, we wished to investigate the effects of ZRF1 overexpression and activation in GC. Consequently, we demonstrated that ZRF1 was frequently overexpressed in GC cell lines and primary GCs, and the overexpression of ZRF1 was identified as an independent factor predicting a poor prognosis. We also demonstrated that knockdown of ZRF1 expression in ZRF1-overexpressing GC cells suppressed the cell proliferation, migration and invasion and induced apoptosis in a p53-dependent manner. Our results provided evidence that ZRF1 could be an important molecular marker for determining the malignant properties of tumors and could be a promising therapeutic target in patients with GC.
Materials and methods

Cell lines and primary tissue samples
A total of five GC cell lines (KATO-III, NUGC4, HGC27, MKN45 and MKN74 cells), a p53-null osteosarcoma cell line (SaOS2), a wild-type p53 osteosarcoma cell line (U2OS) and a fibroblast cell line (WI-38) were used in this study. All cell lines were purchased from RIKEN BioResource Center Cell Bank (Tsukuba, Japan), where the cell lines were authenticated by Short Tandem Repeat profiling before distribution. HGC27 and U2OS cells were cultured in Dulbecco's Minimum Essential Medium (DMEM). SaOS2 cells were cultured in HyClone McCoy's 5A medium (GE Healthcare Life Sciences). The other cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma, St. Louis, MO). All media were purchased from Sigma and supplemented with 100 ml/l fetal bovine serum (Trace Scientific, Melbourne, Australia). All cell lines were cultured in a humidified 37°C incubator with 5% CO 2 . Paraffin-embedded primary GC tissue samples were collected from 133 consecutive GC patients who had undergone curative gastrectomy at the Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine (Kyoto, Japan) between 2001 and 2003. Relevant clinical and survival data were available for all patients. All experimental methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all patients to use their tissue specimens for research purposes, and the study was approved by the institutional review boards of Kyoto Prefectural University of Medicine. None of the patients underwent endoscopic mucosal resection, palliative resection, preoperative chemotherapy or radiotherapy, and none of them had synchronous or metachronous multiple cancers in other organs. Disease clinical and pathological stages were defined in accordance with the International Union against Cancer tumor-lymph node-metastases (TNM) classification (38 
Quantitative RT-PCR
Total RNA was extracted from tissue samples and cell lines using an RNeasy Mini Kit (Qiagen, Valencia, CA). The reverse transcription reaction was performed using a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). The abundance of mRNA was measured by qPCR using a StepOnePlus PCR system (Applied Biosystems), and Cycle threshold (Ct) values were calculated with StepOne Software v2.0 (Applied Biosystems) using TaqMan Gene Expression Assays (Hs00406064_m1 for ZRF1; Applied Biosystems) according to the manufacturer's instructions. The results of gene expression were calculated as a ratio between ZRF1 and an internal reference gene (Hs01060665_g1 for β-actin; Applied Biosystems) that provides a normalization factor for the amount of RNA isolated from a specimen. This assay was performed in triplicate for each sample.
Western blotting
Anti-ZRF1 rabbit monoclonal antibody (H00027000-M09) was purchased from Novus Biologicals (Colorado), and anti-ACTB antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-p53 (DO7) antibody was purchased from Novocastra Laboratories (Newcastle upon Tyne, UK). Anti-caspase-3 antibody, anti-PARP, AKT, phospho-AKT, p21 and phospho-Rb antibody were purchased from Cell Signaling Technology (Cell Signaling Technology). Cells were lysed, and their proteins were extracted using M-PER ® Mammalian Protein Extraction Reagent (Thermo Scientific).
Loss-of-function by siRNA and cell growth analysis
For loss-of-function analysis by the knocking down of endogenous gene expression, each of the siRNAs targeting ZRF1 (Silencer Select Pre-Designed siRNA TM #4427037; Thermo Fisher Scientific) or Luciferase (Luc) 5′-CGUACGCGGAAUACUUCGA-3′ (Sigma, Tokyo, Japan) was transfected into cells (10 nmol/l) using Lipofectamine RNAiMAX (Invitrogen Corporation, Carlsbad, CA) according to the manufacturer's instructions. The knockdown of a target gene was confirmed by Western blotting.
Proliferation assay and cell cycle analysis
For measurements of cell growth, the number of viable cells at various time points after transfection was assessed by a colorimetric water-soluble tetrazolium salt assay (Cell Counting Kit-8; Dojindo Laboratories, Kumamoto, Japan). The cell cycle position was evaluated 72 h after transfection by fluorescence-activated cell sorting (FACS) as described elsewhere (39) .
Apoptotic cell analysis
At 72 h after transfection, the siRNA-transfected cells were harvested and stained with fluorescein isothiocyanate-conjugated annexin V and phosphatidylinositol using an Annexin V Kit (Beckman Coulter, Brea, CA). A Becton Dickinson Accuri™ C6 flow cytometer was used to analyze the proportion of apoptotic cells.
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Transwell migration and invasion assays
Transwell migration and invasion assays were carried out in 24-well modified Boyden chambers (Transwell chamber, BD Transduction, Franklin Lakes, NJ). The upper surface of 6.4 mm diameter filters with 8 µm pores was precoated with (invasion assay) or without (migration assay) Matrigel (BD Transduction). The siRNA transfectants (8 × 10 5 cells per well) were seeded into the upper chamber with serum-free medium. Complete growth medium was added to the lower well of each chamber. After 22 h of incubation, the migrated or invasive cells on the lower surface of the filters were fixed and stained with Diff-Quik stain (Sysmex, Kobe, Japan), and the stained cell nuclei were counted directly in triplicate as described elsewhere (40) (41) (42) .
Immunohistochemistry
Primary tumor samples were fixed with 10% formaldehyde in phosphatebuffered saline and routinely embedded in paraffin. A horseradish peroxidase (HRP) staining method was used. In brief, after deparaffinization, antigen retrieval was performed by heating the samples in 10 mmol/l citrate buffer (pH 9.0) at 95°C for 60 min. Endogenous peroxidases were quenched by incubating the sections for 20 min in 3% H 2 O 2 . After treatment with Block Ace (Dainippon Sumitomo Pharmaceutical, Osaka, Japan) for 30 min at room temperature, the sections were incubated at room temperature for 1 h with anti-ZRF1 antibody (1:500) or at 4°C overnight with anti-p53 antibody (DO7, Novocastra Laboratories; 1:200). Phosphatebuffered saline was used for all dilutions and washings. The bound primary antibody was detected with EnVision™+ Horse Radish Peroxidase Systems (EnVision+ Dual Link System-HRP; Dako North America, Inc., Carpinteria, CA). HRP labeling was visualized using color development with diaminobenzidine tetrahydrochloride. Slides were counterstained with Mayer's haematoxylin. For the scoring of ZRF1 expression, the intensity (intensity score; 0 = negative, 1 = weak, 2 = strong) and the percentage of the total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed ZRF1 were evaluated for each case. Expression of ZRF1 was graded as high expression (intensity plus proportion scores ≥ 3 of tumor cells showing immunopositivity), or low expression (intensity plus proportion scores ≤ 2 of tumor cells showing immunopositivity) using high-powered (×200) microscopy (43) .
For the scoring of p53 expression, the intensity (intensity score; 0 = negative, 1 = weak, 2 = moderate, 3 = strong) and the percentage of the total cell population (proportion score; 0% ≤ 0 < 30%, 30% ≤ 1 ≤ 100%) that expressed p53 were evaluated for each case. A distinct nuclear immunoreaction in both 3 and ≥30% of the cancer cells was judged positive. The remaining cases were judged negative.
Statistical analysis
The clinicopathological categorical variables pertaining to the corresponding patients were analyzed for significance by the Chi-square test or Fisher's exact test. The differences of non-categorical variables between subgroups were tested with the non-parametric Mann-Whitney U-test. For the analysis of survival, Kaplan-Meier survival curves were constructed for groups based on the univariate predictors, and differences between the groups were tested with the log-rank test. Univariate and multivariate survival analyses were performed using the likelihood ratio test of the stratified Cox proportional hazards model. Differences were assessed with a two-sided test and were considered significant at the P < 0.05 level.
Results
Overexpression of ZRF1 in GC cell lines
Quantitative RT-PCR analysis was performed to test whether ZRF1 is overexpressed in GC cell lines compared with the normal organs ( Figure 1A ). ZRF1 mRNA overexpression was observed in GC cell lines (4/5 lines, 80.0%) and the testis compared with normal stomach, the other normal organs and the fibroblast cell line WI-38, suggesting that this gene is a cancertestis antigen. ZRF1 protein expression seemed to be correlated with the mRNA expression in GC cell lines by western blotting using a ZRF1-specific antibody ( Figure 1B) . We used representative osteosarcoma cell lines (SaOS2; p53-null, U2OS; wild-type p53) and examined the status of a TP53 mutation in the GC cell lines, including these osteosarcoma cell lines by western blotting. These statuses of TP53 mutations in various cell lines were positively associated with those in the database (http:// p53.free.fr/index.html; W: wild-type TP53, M: mutant TP53). Note that, among TP53-mutated GC cell lines, KATO-III and HGC27 cells have a p53 gene deletion and a frameshift mutation, respectively.
Immunohistochemical analysis of ZRF1 expression in primary tumors of GC
Because ZRF1 was overexpressed in almost all GC cell lines, it was hypothesized that ZRF1 was also highly expressed in GC tissues and would be associated with carcinogenesis and malignant outcomes. We examined the prognostic and clinicopathological significance of ZRF1 expression in primary tumor samples of GC based on the immunohistochemical staining pattern of this protein. ZRF1 was observed mainly in the cytoplasm of cancer cells. We classified 133 GC samples into positive and negative groups according to the intensity and proportion of ZRF1 staining among tumor cells, as described in Materials and methods. In primary cases, ZRF1 expression was negative in the non-tumorous gastric mucosal cell population ( Figure 1C ). Kaplan-Meier survival estimates showed that ZRF1 immunoreactivity in tumor cells was significantly associated with a worse cause-specific survival according to the extent of each intensity and proportion score ( Figure 1D and E). In the total scores of intensity plus proportion ( Figure 1F ), the ZRF1 high expression group, with scores ≥3 for tumor cells showing immunopositivity, presented a significantly poorer overall survival (P = 0.0002, log-rank test) ( Figure 1G ) and relapse-free survival (P = 0.0003, log-rank test) than the low expression group ( Figure 1H ).
Association between ZRF1 protein abundance and clinicopathological characteristics in primary cases of GC
To test the hypothesis that the ZRF1 protein abundance contributes to malignant features in GC, we assessed the expression of ZRF1 in primary GC tissues by immunohistochemistry. The relationship between the expression of ZRF1 and clinicopathological characteristics is summarized in Table 1 . Protein expression of ZRF1 was significantly associated with histopathological differentiation, venous invasion, lymphatic invasion and advanced stage, whereas other characteristics were not. The Cox proportional hazards regression analysis (Table 2) identified ZRF1 immunoreactivity in tumor cells as an independent factor predicting a worse overall survival rate (hazard ratio 4.92; 95% confidence interval: 1.6-21.1) along with advanced T and N stage and venous invasion. After gastrectomy, the protein expression of ZRF1 was significantly associated with recurrences (P < 0.0001), especially peritoneal (P = 0.0069) and lymphatic metastases (P = 0.0242) ( Table 3 ).
Suppression of cell proliferation by knockdown of ZRF1 and the knockdown effect according to TP53 mutation status
To gain insight into the potential role of ZRF1 as an oncogene whose overexpression could be associated with gastric carcinogenesis, we first performed a cell proliferation assay using siRNAs specific to ZRF1 to investigate whether knockdown of ZRF1 staining were determined as follows: 0 = negative, 1 = weak, 2 = strong. Kaplan-Meier plots depending on the scores of the intensity (D) and proportion (E) of specific immunostaining of ZRF1. The log-rank test was used for statistical analysis. P < 0.05 was considered statistically significant. For the scoring of ZRF1 expression, the intensity (intensity score; 0 = negative, 1 = weak, 2 = strong) and the percentage of the total cell population (proportion score; 0 < 10%, 10% ≤ 1 < 33%, 33% ≤ 2 < 66%, 66% ≤ 3 ≤ 100%) that expressed ZRF1 were evaluated for each case. Expression of ZRF1 was graded as high expression (intensity plus proportion scores ≥3 for tumor cells showing immunopositivity) or low expression (intensity plus proportion scores ≤2 for tumor cells showing immunopositivity) (F). Overall survival (G) and relapse-free survival (H) rates of GC patients (as determined by Kaplan-Meier plots) depending on the combination scores of intensity and proportion in ZRF1 expression.
would suppress the proliferation of GC cells that overexpress ZRF1. In the p53 wild-type cell line, NUGC4 (Figure 2A ), expression of ZRF1 was efficiently knocked down by the introduction of a ZRF1-specific siRNA (siRNA-ZRF1) compared to a luciferase-specific siRNA (siRNA-Luc) as a negative control. The proliferation of the cell line was particularly suppressed after the knockdown of endogenous ZRF1 expression. However, in the p53 mutant cell line, HGC27 ( Figure 2B ), suppression of cell proliferation was detected, but the degree of suppression was smaller compared to that in NUGC4 despite the complete knockdown of ZRF1. To validate the relationship between p53 status and ZRF1 in multiple GC cell lines, we performed these experiments using cell lines MKN45 ( Figure 3A ) and U2OS (Supplementary Figure 1A , available at Carcinogenesis Online) (to confirm the results for p53 WT) and MKN74 ( Figure 3B ) and SaOS2 (Supplementary Figure 1B , available at Carcinogenesis Online) (to confirm the results for the p53 mutant). To confirm that the effects of the ZRF1 knockdown were specific to the target, we performed a proliferation assay using fibroblast cell line WI-38 as a ZRF1 negative cell line. The effects of the introduction of siRNA-ZRF1 were not found in WI-38 ( Supplementary Figure 2 , available at Carcinogenesis Online).
Cell cycle analysis and apoptosis assay by silencing of ZRF1 expression using fluorescence-activated cell sorting
To investigate the reasons for the suppression of cell proliferation by knockdown of ZRF1, we performed a cell cycle analysis and apoptosis assay. FACS analysis demonstrated that transfection of TP53 wild-type NUGC4 (Figure 2A ) and MKN45 ( Figure 3A ) with siRNA-ZRF1 resulted in an accumulation of cells in the sub-G1 phase compared with transfection with control siRNA. In the TP53 mutant HGC27 ( Figure 2B ) and MKN74 ( Figure 3B ), transfection with siRNA-ZRF1 resulted in an accumulation of cells in the G0/G1 phase compared with transfection with control siRNA. The apoptotic cell analysis showed that transfection of TP53 wild-type NUGC4 (Figure 2A ) and MKN45 ( Figure 3A ) with siRNA-ZRF1 increased early apoptosis (annexin V-positive/ PI-negative) and late apoptosis (annexin V/PI-double positive) at 72 h after transfection compared with transfection with control siRNA (Figure 2A ). In the TP53 mutant HGC27 ( Figure 2B ) and MKN74 ( Figure 3B) ; however, there was no difference by transfection with siRNA-ZRF1. Western blotting showed that transfection of TP53 wild-type NUGC4 (Figure 2A ) and MKN45 ( Figure 3A ) with siRNA-ZRF1 induced the cleavage of caspase 3 and PARP. In the TP53 mutant, HGC27 ( Figure 2B ) and MKN74 ( Figure 3B ) transfected with siRNA-ZRF1, the cleavage of caspase 3 and PARP was not found. These findings suggested that the knockdown of ZRF1 overexpression in TP53 wild-type cells induce cell apoptosis through caspase activation. However, in p53 mutant cells, knockdown of ZRF1 overexpression did not induce cell apoptosis but did induce cell cycle arrest. Namely, ZRF1 might be related to cell apoptosis and the cell cycle in a TP53 mutationdependent manner.
Suppression of cell migration and invasion by downregulation of ZRF1 expression
As shown in Table 1 , protein expression of ZRF1 was significantly associated with venous invasion and lymphatic invasion in clinical samples. To confirm the relation between ZRF1 and cell migration and invasion in vitro, transwell migration and invasion assays were performed. We examine the ability of TP53 wild-type NUGC4 and TP53 mutant HGC27 cells transfected with siRNA-ZRF1 to move through pores under different conditions. An uncoated membrane was used for the migration assays, whereas a Matrigel-coated membrane was used for the invasion assays. In Figure 2 , the numbers of NUGC4 and HGC27 cells that migrated into the lower chamber were significantly lower for siRNA-ZRF1-transfected cells than for siRNA-control-transfected cells under both conditions. The results suggest that the overexpression of ZRF1 can enhance the ability of GC cells to migrate and invade in both the p53 wild-type and the p53 mutant-type cell lines.
Molecular mechanisms by which overexpression of ZRF1 contributes to malignant potential in GC cells
The PI3K/AKT pathway is frequently activated in cancers and is important for tumor cell growth and survival (44) . Knockdown of ZRF1 expression by transfection with siRNA-ZRF1 suppressed the phosphorylation activation of AKT, induced the production of p21 and induced the phosphorylation inactivation of Rb in both TP53 wild-type and TP53 mutant cells (NUGC4 and HGC27: Figure 2C , MKN45 and MKN74: Figure 3 ). These results suggested that overexpression of ZRF1 induced cell migration and invasion through the activation of AKT. In addition, the overexpression of ZRF could induce cell cycle arrest through the regulation of AKT, p21 and Rb in a p53-independent manner in TP53 mutant cells. Figure 2D shows a hypothetical model of the overexpression/activation of ZRF1 in GC cells.
Relationship between the protein expression of ZRF1 and p53 in primary cases of GC
We examined the relationship between the protein expression of ZRF1 and p53 in primary tumor cells. Because a good correlation is known to exist between the accumulation of p53-DO7 protein and the presence of TP53 gene mutations, especially missense mutations (45, 46) , we used immunohistochemistry to evaluate the TP53 mutation status. We evaluated p53 expression and ZRF1 expression in the slices cut from the same FFPE blocks in this study. As a result, of 133 cases of GC, tumors showing a positive p53-DO7 immunoreactivity were detected in 37 cases (27.8%) (Supplementary Figure 3A , available at Carcinogenesis Online). p53 expression was not observed in non-tumorous gastric mucosal cells. No significant correlations were found between ZRF1 and p53-DO7 immunohistochemical staining patterns (P = 0.3244). Kaplan-Meier survival estimates showed that the expression of p53 was not associated with overall survival (P = 0.3735, logrank test; Supplementary Figure 3B , available at Carcinogenesis Online), and no significant prognostic difference was found between p53-DO7-positive and negative tumors in both the ZRF1 low expression and ZRF1 high expression groups. However, the patients with p53-DO7 negative and ZRF1 negative GC showed specifically favorable prognostic outcomes, and the patients with both p53-DO7 and ZRF1 positive GC showed specifically worse prognostic outcomes (Supplementary Figure 3C , available at Carcinogenesis Online). Regarding the pattern of recurrence after curative resection from the view point of p53-DO7 status, the protein expression of ZRF1 significantly increased the rate of hematogenous recurrence especially in the p53-DO7-positive group (Table 3 ). In the ZRF1 positive group, p53-DO7 high expression was significantly associated with histopathological differentiation (P = 0.0208) and advanced T stage (P = 0.0282) (Supplementary Table III , available at Carcinogenesis Online).
Discussion
In this study, we demonstrated that ZRF1 was frequently overexpressed in GC cell lines and primary GC, and the overexpression was significantly associated with tumor malignant features and poor outcomes. Furthermore, knockdown of ZRF1 inhibited cell proliferation, migration and invasion. These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC. Recently, it has been revealed that monoubiquitination of histones is one of the most representative epigenetic markers and is intimately involved with Polycomb protein-mediated transcriptional gene silencing (47) . The Polycomb complexes have crucial functions for cellular differentiation and development (47) , and the deregulation of Polycomb complexes is often identified in several cancers (14) . One of the main Polycomb protein complexes, Polycomb repressive complex 1 (PRC1), contains the E3 ligase RING1B and can ubiquitinate histone H2A (48) . Previous studies have demonstrated that ZRF1 is an H2A-ubiquitin binding protein and can displace PRC1 from chromatin and deubiquitinate histone H2A, resulting in the activation of its target genes (16, 49) . Demajo et al. (34) demonstrated that overexpression of ZRF1 could repress anti-proliferative genes and pro-apoptotic genes in acute myeloid leukemia. However, the detailed mechanisms by which ZRF1 contributes to tumorigenesis and tumor progression still remain unclear. In this study, we clearly demonstrated that overexpression of ZRF1 inhibited cell apoptosis in an p53-dependent manner and increased cell proliferation through the regulation of AKT, p21 and Rb; and migration and invasion through the activation of AKT regardless of the mutation status of TP53.
These ZRF1 functions, which were dependent on the p53 mutation status, could be validated by experiments using p53 wild sarcoma cells, U2OS and all p53 null sarcoma cell lines, SaOS2. The results indicated that p53 might be an potential important substrate for ZRF1. Therefore, we assessed whether a correlation between p53-DO7 and ZRF1 immunoreactivity might be a more useful predictor for survival of patients with GC. In the p53-DO7-positive group, the patients with low ZRF1 expression GC showed a specifically favorable prognosis; however, the patients with high ZRF1 expression GC showed specifically worse prognostic outcomes with a high incidence of hematogenous recurrence. A previous study also demonstrated that p53-DO7-positive GC was significantly associated with more vascular involvement and liver metastasis (50). Thus, ZRF1 might contribute to malignant potential especially in p53-DO7-positive GC. Consequently, we considered that ZRF1 targeted therapy has the potential to make a significant improvement in prognostic outcomes especially for patients with p53-DO7 positive GC. The present study has some limitations. One major limitation was that we did not have more information about the genetic alterations/copy number variations of ZRF1 in GC cell lines and primary tumors. Therefore, we could not completely exclude the potential effect of other 7q genes associated with genomic amplification of 7q22 apart from ZRF1. However, the rate of genomic amplification of 7q22 in GC in previous studies was lower than the rate of overexpression of ZRF1 (61%, 81/133) in our study (28) (29) (30) . Therefore, the effect of other 7q22 genes associated with genomic amplification of 7q22 may not have been so high. Of importance, this is the first report to show that overexpression/activation of ZRF1 certainly has an oncogenic role with or without genomic high-copy amplification, and ZRF1 is a potential therapeutic target in GC. We clearly demonstrated the frequent overexpression of ZRF1 and its prognostic value in patients with GC. Although studies of larger cohorts are needed to validate these findings before moving to clinical settings, our results provide evidence that ZRF1 could be a crucial molecular marker to determine the malignant properties of GC cells and could be a promising therapeutic target regardless of the mutation status of TP53. In particular, patients with p53-DO7-and ZRF1-positive GC should be considered for ZRF1-specific targeted therapy in an effort to improve the prognosis.
